Sequel Med Tech’s twiist now available nationwide

MANCHESTER, N.H. – Sequel Med Tech has announced broad national availability of its twist Automated Insulin Delivery (AID) System powered by Tidepool, following clearance by the U.S. Food and Drug Administration in 2024 and a subsequent controlled launch. “With twiist now accessible to more people than ever before, we’ve reached a meaningful milestone for Sequel and for people living with type 1 diabetes,” said Sequel CEO and Co-Founder Alan Lotvin, MD. “twiist was built to fit into real life, combining precise insulin delivery, an advanced algorithm, and a user experience shaped by the lived experience of people with diabetes. The result is automated insulin delivery designed to deliver the benefits of automation with precision while creating greater personalization and choice.” Built on Sequel’s proprietary iiSure Technology, twiist enables earlier detection of delivery issues, alerting users to blockages up to nine times faster than other AID systems, potentially reducing the risk of unexplained high glucose and giving users the time to take action before experiencing severe high blood sugar or DKA2. Cleared for people ages six and older with Type 1 diabetes, the system is designed to adjust basal insulin to individual dosing needs while offering personalization features that let people manage their diabetes in a way that fits their lives. It is powered by the twiist Loop algorithm, based on the community-developed Tidepool Loop, enabling the system to automatically adjust basal insulin delivery based on continuous glucose monitor (CGM) readings, personalized settings and predicted glucose levels.